Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006‐intermediate‐risk trial

In this randomized phase 3 study, the FILO group tested whether the addition of 6 mg/m2 of gemtuzumab ozogamycin (GO) to standard chemotherapy could improve outcome of younger patients with de novo acute myeloid leukemia (AML) and intermediate‐risk cytogenetics. GO arm was prematurely closed after 2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of haematology 2021-07, Vol.107 (1), p.111-121
Hauptverfasser:	Bouvier, Anne, Hamel, Jean‐François, Delaunay, Jacques, Delabesse, Eric, Dumas, Pierre‐Yves, Ledoux, Marie‐Pierre, Peterlin, Pierre, Luquet, Isabelle, Roth Guepin, Gabrielle, Bulabois, Claude Eric, Gallego Hernanz, Maria Pilar, Guillerm, Gaëlle, Guieze, Romain, Hicheri, Yosr, Simand, Célestine, Himberlin, Chantal, Hunault‐Berger, Mathilde, Bernard, Marc, Jourdan, Eric, Caillot, Denis, Dorvaux, Véronique, Tavernier, Emmanuelle, Daguindau, Etienne, Banos, Anne, Ojeda‐Uribe, Mario, Gyan, Emmanuel, Alexis, Magda, Marolleau, Jean‐Pierre, Turlure, Pascal, Bouscary, Didier, Humbrecht, Catherine, Zerazhi, Hacène, Béné, Marie‐Christine, Pigneux, Arnaud, Carre, Martin, Ifrah, Norbert, Blanchet, Odile, Vey, Norbert, Récher, Christian, Cornillet‐Lefèbvre, Pascale
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Adolescent Adult Chemotherapy Cluster Analysis Cytogenetic Analysis Cytogenetics Disease-Free Survival DNA Mutational Analysis Epigenetics Female Gemtuzumab - pharmacology gemtuzumab ozogamycin Gene Expression Profiling Gene Expression Regulation, Leukemic gene mutations Hematopoietic Stem Cell Transplantation Humans intermediate‐risk cytogenetics Karyotyping Leukemia Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Life Sciences Male Medical prognosis Middle Aged Mutation Myeloid leukemia Prognosis Remission Remission Induction Risk Toxicity Transplantation unsupervised clustering Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this randomized phase 3 study, the FILO group tested whether the addition of 6 mg/m2 of gemtuzumab ozogamycin (GO) to standard chemotherapy could improve outcome of younger patients with de novo acute myeloid leukemia (AML) and intermediate‐risk cytogenetics. GO arm was prematurely closed after 254 inclusions because of toxicity. A similar complete remission rate was observed in both arms. Neither event‐free survival nor overall survival were improved by GO in younger AML patients (
ISSN:	0902-4441 1600-0609
DOI:	10.1111/ejh.13626